Skip to main content
. 2021 Mar 17;21:37–46. doi: 10.1016/j.omto.2021.03.008

Figure 3.

Figure 3

SFV-AM6-124T infects GL261 tumors ex vivo and in vivo

(A) Schematic presentation of the SFV-AM6-124T genome. (B and C) 50,000 PFUs of SFV-AM6-124T virus was added on top of brain slice cultures with GL261 tumors. Samples were fixed 2 days after infection and stained with anti-SFV antibody (green), anti-CD31 (red), and Hoechst (blue). (C) Magnified image of the infected tumor area. (D–G) Intraperitoneally administered SFV-AM6-124T infects GL261 brain tumor in vivo. Representative images from oncolytic regions in orthotopic GL261 tumors from mice treated with SFV-AM6-124T. (D) Staining for SFV proteins in GL261 sample collected from SFV-AM6-124T-treated mice 2 days after last virus dose. Nuclei were stained with Hoechst (blue). (E) Staining for cleaved caspase-3 in the same sample as in (D). (F and G) Sample collected from SFV-AM6-124T-treated mice at the endpoint. (F) Staining for SFV proteins (green) and CD11c (magenta). (G) Staining for cleaved caspase-3 (green) and CD11c (magenta).